The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

A novel topical gel, HT-001, has shown potential as a treatment for cutaneous side effects from epidermal growth factor receptor inhibitor ... regulatory pathway, according to the company website.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

such as increasing the function of oestrogen receptor-α and E2F1, the activity of the insulin-like growth factor 1 (IGF1) signalling pathway, epidermal growth factor receptor (EGFR) and ERBB2 ...

The PI3K signaling pathway is commonly dysregulated ... adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has an abnormal ...

As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...

Anxiety disorders, characterized by an excessive apprehension about real or perceived threats and dysfunctional behaviors ...

Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report), reducing the price target ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) yesterday and set a price ...